Hasn't OSIR lost a couple CEOs, CFO and chief science over the past 2 years? That speaks volumes.
If you believe Mimedx, MTF lost on Epifix/Amniofix and there was only minor question on auxiliary embossing patent. MTF is basically finished.I imagine this case won't be finished for awhile and Mimedx will maintain an injunction against their patent infringement.
VA Grafix Price List
Grafix® PRIME Cellular Repair Matrix Frozen 2cm x 1.5cm $775.00
Grafix® PRIME Cellular Repair Matrix Frozen 5cm x 5cm $2,400.75
Grafix® PRIME Cellular Repair Matrix Frozen 3cm x 2cm $1,100.00
Grafix® PRIME Cellular Repair Matrix Frozen 4cm x 3cm $1,500.00
Grafix® CORE Cellular Repair Matrix Frozen 2cm x 1.5cm $775.00
Grafix® CORE Cellular Repair Matrix Frozen 3cm x 2cm $1,100.00
Grafix® CORE Cellular Repair Matrix Frozen 4cm x 3cm $1,500.00
Grafix® CORE Cellular Repair Matrix Frozen 5cm x 5cm $2,400.75
Grafix® XC Cellular Repair Matrix Frozen 7.5cm x 15cm $5,850.00
LessVA Grafix Price List
I see some huge products on the horizon, like a Tsunami rolling toward the beach. If a company doesn't want to pay up, sure Mimedx would benefit from waiting until 2017 to sell the company.
Yes currently growing 75%, but look at Collafix. This will potentially be used in every joint, tendon, muscle or other connective tissue repair. We are talking 4-5 million procedures per year. Even at $500 per graft, this would dwarf current revenues. An orthopedic company who wants to be a serious contender would be foolish to pass on this product.
I use a lot of Epifix and have very good success with the product. Several growth and revenue catalysts are in the works. Trailing 12 month growth close to 100% and 2015/2014 about 70%. With 2016/2015 about 40-50%. PE now about 60. Looks like a value play.
I recall the study regarding ligament regeneration using Collafix. A joint ligament is just a thickened sheet of dense connective tissue and being able to predictably regenerate it with early exercise and something off the shelf is very big. Current solution is cadaver or steal from the other side and delay return to physical activity. This has the potential to be used in every joint/muscle surgery which numbers in the millions per year in theUS.
The old Collafix required extensive FDA trials if I remember. Mimedx has lined or attached Amniofix sheet to the Collafix which will allow a 510 designation and require less FDA involvement. 510 takes a minimum 90 days to get approval, but throw in a clinical trial and about a year. So, by getting a 510 it allows faster, easier approval and Amniofix brings in stem cells for faster, more complete ligament regeneration and collagen sheath allows faster return to exercise. It appears to be a winner to me. I just don't know what kind of credit it would give to the company being sold early 2016 with revenue projection for 2016 being 250 million.
Interesting analysis and accurate. Collafix will be bigger than Epifix/Amniofix. There are between 250-300,000 ACL repairs in the US each year and it will be used on other tendon/ligament/muscle repairs as well. Plus if used in joint replacement, there will be 4 million knee/hip replacements in the US each year by 2030. I would like to see Collafix hit the market or international start to develop, but I do agree with you on the injectable and fatigue factor. I think also if a reasonable offer was submitted, consideration should be given.
It amazes me that something that does not work is still referred to as the standard of care. At some point everyone has to edit their doctrine and say a proven high success rate product is the NEW standard of care. Marketing could help get the word out.
It is all the same OCD person from OSIR board. This person also uses aliases on the OSIR board to extoll virtues of OSIR. Weird dude for sure. I can tell you, I use a lot of Epifix and he is flat wrong trying to promote Grafix. It is like other Organogenesis products.